Epigenetyka - where science meets business

March 12, 2024
The conference
Epigenetyka – where science meets business

Despite that we now know the sequence of human genome, genetics does not explain origins of most diseases - especially the diseases that currently challenge our societies.  At the same time after about 40 years of research, epigenetics provides comprehensive answers as to how diseases develop. 

The dynamic development of epigenetic research has now reached the stage of commercialization, and the sector is becoming attractive to the capital market, creating new investment opportunities. 

What does this mean for clinical research stakeholders and investors? 

What opportunities does the market for epigenetic testing bring?

Innovations in the field of epigenetics have a chance to revolutionize cancer clinical management. That is because epigenetic research led to development of blood-based diagnostic test for early cancer detection and early cancer diagnosis significantly increases chance of survival and dramatically reduces the cost of cancer treatment. A startup developing such tests was recently acquired for more than 7 billion USD. Moreover, commercialization of innovations originating from epigenetic research has already led to the establishment of "logevity" clinics around the world with the main goal to extend our life span and prevent development of diseases that affect us as we age.

The conference 

Epigenetics - where science meets business 

will be an opportunity to exchange knowledge, as well as practical experience in funding startups and bringing diagnostic products to market based on innovation in the field of epigenetics.

Who are invited to attend the conference?

The conference aims to bring together stakeholders in clinical diagnostic research (representatives of the medical and scientific communities, patient organizations, government officials, representatives of pharmaceutical, biotechnology and CRO companies, students of medical faculties and biomedical specialties), as well as representatives of Venture Capital, Business Angels and institutional investors interested, in opportunities in the rapidly growing market of epigenetic innovation.

Prelegenci

Nikolay Kirov

Praktyk z zapleczem naukowym. Od 1996 r. wykładowca, doradca, mówca inspiracyjny, trener w zakresie: 

- negocjacji, budowania relacji i kreowania wartości dodanej w biznesie 

- przywództwa, strategii i wdrażania zmian organizacyjnych  

- rozwiązywania konfliktów i komunikowania się 

- negocjacji strategicznych i międzykulturowych 

- zarządzania sobą, zespołem oraz zarządzania własną energią: ciałem, emocjami i umysłem. 

Instruktor Calligraphy Health System - Calligraphy Yoga - odmiana QiGong oraz ZEN Coaching praktyk. 

Certyfikowany w narzędziach diagnostycznych: FRIS, MPA, MTQ48, Reiss Motivation Profile, Faced5. 

Od 24 lat ponad 150 000 osób brało udział w jego wykładach, szkoleniach i sesjach strategicznych podczas realizacji Programów Rozwojowych dla Korporacji i Przedsiębiorców, studiów podyplomowych, programów Master of Business Administration: Executive MBA, MBA IT, MBA HR, MBA FINANSE, MBA dla Inżynierów, MBA dla kadry Medycznej, a także w międzynarodowym programie Executive MBA realizowanym w języku rosyjskim na Białorusi. Wykładowca „Kozminski CAMP - Advanced Management Program” - realizacja Warszawa - Barcelona, na którym prowadzi zajęcia w EADA Business School. 

Specjalizuje się w projektowaniu programów talentowych i rozwojowych dla menedżerów - pod indywidualne potrzeby organizacji.  

Twórca Akademii Negocjacji, Budowania Relacji i Kreowania Wartości w Biznesie oraz studiów podyplomowych Strategiczne Zarządzanie Sprzedażą i Zespołem Sprzedaży”. Jest współtwórcą programu „Life & Business Energy Management” i projektu LifeEnergy.pl 

Na swoich kursach pokazuje, jak umiejętności negocjowania i budowania relacji w biznesie przekładają się bezpośrednio na korzyści ekonomiczne i zadowolenie partnerów, a także jak podpisywać korzystniejsze długoterminowo kontrakty. 

Jest partnerem i członkiem zarządu Kirov Strategic Negotiators Sp. z o.o., LifeEnergy.Pl, członkiem Zarządu Fundacji BARGEWORK, członkiem Rady Naukowej Fundacji „Pasja do Edukacji i Rozwoju”, członkiem Kapituły Nagrody PNSA - Polish National Sales Awards, członkiem kapituły nagrody "Lwy Koźmińskiego" oraz członkiem rady programowej czasopisma "Personel i Zarządzanie".

Dyrektor Kozminski MBA - obszar Przywództwo i Negocjacje. Koordynator merytoryczny programu studiów Koźmiński MBA dla Inżynierów. Wcześniej - wieloletni członek kolegium redakcyjnego czasopisma "Management and Business Administration. Central Europe" oraz wieloletni Dyrektor ds. Strategii i Rozwoju - Kozminski Executive Business School - Centrum Doradztwa i Kształcenia Menedżerów - Akademii Leona Koźmińskiego.  

Jest również opiekunem i promotorem kilkudziesięciu strategicznych projektów doradczych prowadzonych w ramach programów MBA, oraz opiekunem i promotorem ponad 200 projektów doradczych dla administracji publicznej.

Jego główne zainteresowania badawcze to negocjacje i budowanie relacji z partnerami strategicznymi w biznesie, a główne obszary doradztwa i szkoleń – negocjacje i budowanie relacji i kreowanie wartości w biznesie, negocjacje strategiczne, tworzenie wspólnych przedsięwzięć oraz wdrażanie zmian strategicznych dla firm z branż: finansowej, motoryzacyjnej, medycznej, farmaceutycznej, FMCG, turystycznej, budowlanej, wydawniczej, turystycznej, logistyki i przemysłu oraz instytucji publicznych. 

W latach 2005-2008 był koordynatorem regionalnym największego projektu edukacyjnego w Europie (ponad 40 mln zł) "Studia podyplomowe dla kadr zarządzających i pracowników przedsiębiorstw”, realizowanego przez Stowarzyszenie Uczelni Wyższych "Edukacja dla Przedsiębiorczości" w ramach SPORZL 2.3,A. 

dr hab. n. med. Edyta Borkowska

National Consultant in Medical Laboratory Genetics

I graduated from the laboratory medicine course, the Faculty of Pharmacy at the Medical University of Lodz. I did my master’s degree in the Medical Genetics Department under the direction of Prof. Bogdan Kałużewski. In the same department I commenced work on my doctoral thesis “Detection of TP53 Gene Mutation with MSSCP Method in Bladder Cancer Cases”, under the Division for Doctoral Studies of the Medical University of Lodz. I defended my dissertation in 2004. I have been involved in oncological research since the beginning of my professional career. I worked on this subject realizing two scientific grants of the Ministry of Science and Higher Education. I applied the real-time PCR technique and I did the marking of the expression of selected genes involved in the development of bladder cancer. I adapted artificial neural networks and I tried to create the risk calculator for bladder cancer recurrence and progression. I also utilised Self Organising Kohonem Maps, which are a kind of independent artificial intelligence, in order to detect correlations between seemingly unrelated factors. I did part of that research in Great Britain during my international internship at Oxford University. While being there, I had a chance to work with Prof. James Catto from the University of Sheffield on the role of noncoding RNA in the process of the bladder cancer development. I have been continuing this subject in my research since then. At present, my research focuses on the role and the use of noncoding RNA (both microRNA and long noncoding RNA) in cancer diagnosis and prognosis. We carry out tests both in tumour tissue and in the so called liquid biopsy, i.e. in nucleic acids isolated from patients’ blood and urine. We utilize modern techniques, such as digital PCR and Next Generation Sequencing. The latter technique is the one which I would like to concentrate on, working with it on the large scale, mainly, I mean, RNA sequencing and analysing obtained results. My aim is also further application of results in order to adjust treatment to the genetic profile of a tumour as well as to the so called personalized medicine.

Łukasz Więch

Panel discussion Barriers to the medical diagnostics market

A Visionary of Healthcare, Leader of studies in this area at Kozminski University in Warsaw. Expert in clinical trials, healthcare management, negotiations. Academic teacher with over 10 years of experience. A graduate of the Kozminski University (KU) in the field of Kozminski MBA for Medical Proffesionals and the Faculty of Medicine of the Medical University of Warsaw. Physician - public health specialist. Manager experienced in leading large teams set in the matrix space. An educator by passion and experience. Scientific Assistant at KU, working on the role of games and simulations in healthcare management education.

Interested in creating innovative business solutions and partnerships in line with the win-win philosophy. He develops himself in the field of creating concepts supporting leaders in health care - coaching, mentoring, effective leadership, organization management, change management and others. Inspired by effective, holistic healthcare management that takes into account both processes, material resources and people in the organization - employees and patients.

prof. Maciej Banach

Panel discussion Barriers to the medical diagnostics market

Prof. Maciej Banach was an Undersecretary of State at the Ministry of Science and Higher Education of the Republic of Poland (2010-2012), and a President of the 2nd largest hospital in Poland. - the Polish Mother's Memorial Hospital - Research Institute (PMMHRI) (2014-2021). He is a Head of Cardiovascular Research Centre at University of Zielona Gora, Head of Department of Preventive Cardiology and Lipidology at the Medical University of Lodz (MUL), and Professor Consultant at the Department of Cardiology and Congenital Diseases of Adults at the PMMHRI in Lodz, Poland. Since October 2022 he has also joined the Faculty of the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease as an Adjunct Professor (the Johns Hopkins Hospital is ranked as the 4th in the World's Best Hospitals 2023 by Newsweek).
He is a Secretary of the European Atherosclerosis Society (EAS) (2021-2024) and member of the Scientific and Health Policy Advisory Group of the FH Europe. He is a Founder and Head of the Polish Lipid Association (PoLA) (2011-), Founder of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (2012-; www.lbpmcgroup.com) – a group of over 150 worldwide experts aimed to investigate the most important issues in the field of lipid disorders, hypertension, nutrition and cardiovascular risk, as well as the International Lipid Expert Panel (ILEP; https://ilep.eu) (2015-), which has been founded to prepare recommendations in the area of preventive cardiology in the most debatable issues that have not been covered in the existing guidelines. He is also a member of the REPROGRAM Consortium – a group of experts challenging with Covid-19 pandemic, CArdiometabolic Panel of International Experts on Syndemic COVID-19 (CAPISCO), ORCHESTRA Project – EU project dedicated to long-Covid research, and member of 2 largest worldwide databases – the Global Burden of Disease (GDB) (University of Washington, Seattle, US) and Non-Communicable Diseases Risk Factor Collaboration (NCD-RisC, Imperial College of London, UK). He is also Founder and President of the foundation – Think-Tank “Innovation for Health”, which gathers six main health research institutes and over 40 medical business representatives in Poland with main aim to make innovations in the medical area in Poland. He is a Visiting Professor of University of Alabama at Birmingham (UAB) and University of Medicine and Pharmacy Victor Babes in Timisoara, Romania, and University of California at Irvine (UCI).

Arkadiusz Grądkowski

Panel discussion Barriers to the medical diagnostics market

Arkadiusz Grądkowski, as President of The Polish Chamber of Commerce of Medical Devices POLMED since 2020, steers Poland’s foremost organisation representing medical device manufacturers and distributors. His role expanded in 2023 as a board member of MedTech Europe.  
Grądkowski’s career in healthcare includes significant contributions at The Polish Confederation Lewiatan, advising pharmaceutical and cosmetics industries and liaising with public authorities. 
Previously, he was Deputy Director in the Department of Information on Medical Devices at the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. His efforts were crucial in amending the Polish Medical Devices Act and aligning it with EU regulations. Grądkowski represented Poland at the EU Competent Authorities for Medical Devices (CAMD) meetings and worked on European Commission twinning projects in Moldova and Macedonia, focusing on medical product and device trade laws. 
Arkadiusz Grądkowski holds a Master’s degree in law from the Maria Skłodowska-Curie University in Lublin, combining legal expertise with a deep understanding of the medical devices sector. 

Jolanta Kołodziejczyk

Discussion panel Barriers to the medical diagnostics market

From 2003, she has worked at Diagnostyka S.A., where has held the position of Deputy Sales Director. Until 2021, she was the CEO of the largest Polish net of pathology laboratories: Diagnostyka Consilio. Since 2022 she has been a vice president of the genetics laboratories: genXone S.A., Genesis sp. z o.o., Oncogene Diagnostics sp. z o.o. She holds a PhD in the biological science from the Jagiellonian University. 

Szymon Kierat

Discussion panel Barriers to the medical diagnostics market

Specialist of the Notified Body, where he serves as a reviewer of in vitro diagnostic medical devices, clinical expert and auditor. Graduate of Warsaw Medical University and Medical University of Lodz. Laboratory diagnostician - specialist in medical laboratory genetics with more than a decade of experience in the field of laboratory medicine, including genetics of rare diseases, which he gained at the largest Polish clinical hospital, the University Clinical Center of WUM. Member of the Medical Genetics Team at the National Chamber of Laboratory Diagnosticians. Member of scientific societies: European Society of Human Genetics, European Society of Cardiology and Polish Society of Human Genetics.

PhD Marcin Kraśniewski

Discussion panel Funding in the medical diagnostics market

Ph.D. Assistant professor (adjunct) at the Department of Energy Transformation at the University of Economics in Katowice. He specializes in public commercial law, European economic law, energy law, economic regulations, as well as in the infrastructure sector. Author of over 50 publications. Professionally with the energy sector. Polish delegate to the UN Climate Summits COP.

Ewa Kozak

Panel discussion Funding in the medical diagnostics market

Master of Management, Master of Business Administration (MBA)

A graduate of the Faculty of Management at the Warsaw School of Economics and an MBA graduate of the Warsaw School of Economics - Medical University of Warsaw in the field of Health Protection.
Participant of training and business workshops in USA, France, Germany and Spain. Business speaker at nationwide trainings and medical congresses. For over a dozen years, he has been successfully managing entities on the health care and pharmaceutical markets, also in the field of dermatology and aesthetic medicine. Recent business success: she created from scratch and manages the Polish branch of Mesoestetic Pharma Group.

Mesoestetic Pharma Group is a Spanish pharmaceutical company with over 40 years of history, present in over 109 countries around the world. It has its own pharmaceutical factory, R&D department, including a biotechnology and biomedical engineering department using AI to create new molecules and new galenic forms of products. The company has patents protecting technologies used in their own production of cosmetics.

For over a dozen years, she has been associated with the broadly understood health care and pharmaceutical markets in business. For several years, he has been successfully introducing and managing brands on the aesthetic medicine market, working closely with the medical community. From March 2021, Managing Director in the Polish branch of the Spanish pharmaceutical and aesthetic medicine laboratory of Mesoestetic Pharma Group.

PhD Hubert Pachciarek

Panel discussion Funding in the medical diagnostics market

Doctor of economics in the discipline of management and quality sciences, Director of the Technology Transfer Center of the Pomeranian Medical University in Szczecin, CEO of the special purpose vehicle Center of Innovative Technologies PUM sp. z o. o., co-founder of spin-offs in the field of biotechnology and medicine, promoter of academic entrepreneurship, member of the Agreement of Companies Targeted and PACCT. Research and teaching employee of the University of Szczecin, creator of over 30 scientific publications, manager of scientific and teaching projects, member of research teams, conducts research in the areas of foresight methodology, strategic management, inter-organizational cooperation and technology transfer.

Marcin Szczeciński

Panel discussion Funding in the medical diagnostics market

Investment Manager
Marcin Szczeciński is a graduate of law from the University of Lodz and the EMBA program at the Warsaw University of Technology Business School. He also studied at Utrecht University. With nearly 18 years of experience in the pharmaceutical industry, he has been involved in various projects within the drug discovery field at Adamed, contributing to the portfolio development and strategy in this area. He has closely collaborated with scientists on R&D projects for new drugs, gaining insight into their specifics, regulatory requirements, and intellectual property matters. He has secured external funding for these initiatives and has been instrumental in the commercialization of drug candidates, working with clients from big, mid, and Japan pharma. In 2015, he joined Adamed's investment arm, where he is responsible for investing in startup projects addressing unmet medical needs and inefficiencies of healthcare systems.
 

PhD Tomasz K. Wojdacz

Panel discussion Funding in the medical diagnostics market

CEO of MethylDetect ApS, a Danish company marketing diagnostic tests based on epigenetic biomarkers. MethylDetect ApS was built on intellectual property (patents) generated as part of scientific research conducted by Tomasz's research team. MethylDetect ApS has been in business for eight years, seven of which are led by Tomasz and have international operations.

Conference Program:

  • 9:00 - 9:30 Participant registration
  • 9:30 Opening of the conference by

dr hab. n. med. Tomasz K. Wojdacz, CEO MethylDetect ApS Łukasz Więch, MBA, Leader of Studies in Healthcare at Kozminski University dr hab. n. med. Edyta Borkowska, National Consultant in Medical Laboratory Genetics

  • 10:00 - 11:00 Discussion panel Barriers to the medical diagnostics market

​​Presenter: Łukasz Więch, MBA, Leader of Studies in Healthcare at Kozminski University Panelists:  1. prof. Maciej Banach, President of the International Lipid Expert panel (ILEP) 2. Arkadiusz Grądkowski, POLMED President 3. Jolanta Kołodziejczyk, Deputy Sales Director at Diagnostyka S.A. 4. Szymon Kierat, Polish Centre for Testing and Certification 

  • 11:00 - 12:00 Why should business leaders understand epigenetics?, Nikolay Kirov

• What can epigenetics say about longevity and health? • What are the underlying environmental mechanisms and how do they affect health and decision-making (including business)? • Will epigenetics be the best business of the 21st century

  • 12:00 - 13:00 Lunch
  • 13:00 - 14:00 Discussion panel Funding in the medical diagnostics market

Presenter: dr Marcin Kraśniewski, LL.M. Uniwersytet Ekonomiczny w Katowicach Panelists:  1. Ewa Kozak, Managing Director at Mesoestetic Poland 2. dr Hubert Puchciarek, Director of PUM Technology Transfer Center 3. Marcin Szczeciński, Investment Manager ADAMED 4. dr hab. n. med. Tomasz K. Wojdacz, CEO MethylDetect ApS

  • 14:00 - 14:15 Summary of the event
  • 14:15 - 15:15 Networking

Speakers

dr hab. n med. Tomasz K. Wojdacz

dr hab. n med. Tomasz K. Wojdacz jest profesorem Uniwersytetu w Aarhus w Danii oraz profesorem Pomorskiego Uniwersytetu Medycznego w Szczecinie, gdzie obecnie prowadzi zespół naukowy zajmujący się badaniami w dziedzinie epigenetyki klinicznej. Prof. Tomasz K. Wojdacz jest międzynarodowym ekspertem w badaniach epigenetycznych, a swoją pracę naukową rozpoczął na długo przed studiami doktoranckimi w Peter MacCallum Cancer Centre, w Australii. Po zrobieniu doktoratu prowadził badania w takich ośrodkach jak Karolinska Institute w Szwecji czy Aarhus Institute of Advanced Studies w Danii, gdzie był stypendystą Marie Skłodowska-Curie Individual Fellowship. Prof. Tomasz K. Wojdacz jest prezesem Międzynarodowego Towarzystwa Epigenetyki Molekularnej i Klinicznej, a jego doświadczenie zawodowe to nie tylko badania naukowe, ale i komercjalizacja wyników badań. Jest jednym z założycieli i dyrektorem duńskiej firmy z międzynarodowymi operacjami (MethylDetect ApS), którą zbudował na patentach wywodzących się z jego badań naukowych. Tomasz jest też absolwentem ALK MBA dla kadry medycznej. 

LinkedIn: (2) Tomasz K Wojdacz | LinkedIn

Łukasz Więch

A Visionary of Healthcare, Leader of studies in this area at Kozminski University in Warsaw. Expert in clinical trials, healthcare management, negotiations. Academic teacher with over 10 years of experience. A graduate of the Kozminski University (KU) in the field of Kozminski MBA for Medical Proffesionals and the Faculty of Medicine of the Medical University of Warsaw. Physician - public health specialist. Manager experienced in leading large teams set in the matrix space. An educator by passion and experience. Scientific Assistant at KU, working on the role of games and simulations in healthcare management education.

Interested in creating innovative business solutions and partnerships in line with the win-win philosophy. He develops himself in the field of creating concepts supporting leaders in health care - coaching, mentoring, effective leadership, organization management, change management and others. Inspired by effective, holistic healthcare management that takes into account both processes, material resources and people in the organization - employees and patients.

Organizational Information

The conference will be held on March 12, 2024 in a hybrid formula: stationary at Kozminski University in Warsaw (59 Jagiellońska Street) and online for all those who are unable to attend in person.

Partners/Patrons of the Conference

Media Patrons of the Conference

Conference Office
Biuro Organizacji Konferencji